Thursday, January 8, 2015

Global Blood Therapeutics Finds $48M

South San Francisco-based biopharmaceuticals firm Global Blood Therapeutics said this week that it has raised $48M in a Series B funding. The funding came from Wellington Management Company LLP, RA Capital, Deerfield Management, Sabby Capital, Perceptive Life Sciences, along with an un-named public investment fund. The company said the funding will go towards its lead drug candidate, which is aimed at treating sickle cell disease (SCD). Global Blood Therapeutics is led by Ted W. Love.